Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc

DelveInsight's "Open Angle Glaucoma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Open Angle Glaucoma, historical and forecasted epidemiology as well as the Open Angle Glaucoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Open Angle Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Open Angle Glaucoma Market Forecast [https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Open Angle Glaucoma Market Report:

*
The Open Angle Glaucoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In March 2025, Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), a global ophthalmology company, announced that the final patient has completed their last visit in the Whistler Phase 3b trial evaluating NCX 470's dual mechanism of action-nitric oxide and prostaglandin analog-for reducing intraocular pressure (IOP). NCX 470, Nicox's lead clinical candidate, is an innovative NO-donating bimatoprost eye drop currently in Phase 3 development for treating open-angle glaucoma and ocular hypertension.

*
In February 2025, Qlaris Bio, Inc., a clinical-stage biotechnology company focused on addressing unmet needs in severe ophthalmic conditions, has reported positive topline results from two U.S. Phase II trials evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). The Phase II studies, Osprey and Apteryx, achieved all primary and secondary endpoints successfully.

*
In January 2025, Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceuticals and medical technologies for glaucoma treatment, has launched a Phase 2b/3 clinical program for iDose TREX, its next-generation sustained-release therapeutic platform. iDose TREX is designed to resemble the original iDose TR in size and shape but offers nearly double the drug capacity.

*
In October 2024, At the American Academy of Ophthalmology (AAO) 2024 conference in Chicago, Illinois, findings from a Phase II study on the safety of Neurotech Pharmaceuticals' NT-501 encapsulated cell therapy, which secretes ciliary neurotrophic factor (CNTF), were presented. The study focused on neuroprotection in patients with glaucoma. Alexandria M. Dominguez, MS, a research assistant at the Byers Eye Institute at Stanford University, shared the results, which demonstrated that CNTF-secreting implants were well-tolerated by patients with primary open-angle glaucoma, with no severe adverse events reported.

*
In April 2024, Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company dedicated to improving vision and quality of life through innovative therapies for conditions such as wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other ocular diseases, has announced positive Phase 2 results for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in treating patients with open-angle glaucoma or ocular hypertension.

*
In the 7MM, there were 17,280,267 cases of glaucoma overall in 2022. During the projected period (2023-2032), this number is expected to rise at a significant CAGR

*
In the 7MM, there were 7,322,693 cases of diagnosed prevalent glaucoma in 2022. During the study period (2019-2032), there is predicted to be a considerable compound annual growth rate (CAGR) of these cases

*
With 2,251,283 cases estimated to be the highest diagnosed prevalence of Open Angle Glaucoma (OAG) in the US in 2022, it is anticipated that this number will rise sharply in the near future as a result of improving diagnostic tests and population growth.

*
With 649,908 cases of Open Angle Glaucoma (OAG), Germany had the most diagnosed prevalent population of any European nation in 2022. France came in second with 631,650 cases. However, out of the 7MM, Spain had the least number of people with a diagnosis

*
There are numerous medications in the Open Angle Glaucoma pipeline at the moment. Among the most prominent medications for this indication are iDoseTR, NCX 470, PDP-716, AGN-193408, and a few more. Current clinical studies and ongoing research could alter the industry

*
Key Open Angle Glaucoma Companies: OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others

*
Key Open Angle Glaucoma Therapies: Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others

*
The Open Angle Glaucoma epidemiology based on gender analyzed that women are predominantly affected by Open Angle Glaucoma (OAG) in the 7MM

*
The Open Angle Glaucoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Open Angle Glaucoma pipeline products will significantly revolutionize the Open Angle Glaucoma market dynamics.

Open Angle Glaucoma Overview

Open-angle glaucoma is a chronic eye condition characterized by gradual damage to the optic nerve, often caused by increased pressure within the eye (intraocular pressure). It is the most common form of glaucoma and develops slowly over time, usually without noticeable symptoms in the early stages. If left untreated, it can lead to progressive vision loss and, eventually, blindness. Regular eye exams are crucial for early detection and management.

Get a Free sample for the Open Angle Glaucoma Market Report

https://www.delveinsight.com/report-store/open-angle-glaucoma-market [https://www.delveinsight.com/report-store/open-angle-glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Open Angle Glaucoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Open Angle Glaucoma Epidemiology Segmentation:

The Open Angle Glaucoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalent Cases of Glaucoma in the 7MM

*
Total Diagnosed Prevalent Cases Glaucoma in the 7MM

*
Type-specific Diagnosed Prevalent Cases of Glaucoma in the 7MM

*
Type-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM

*
Gender-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM

*
Age-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM

Download the report to understand which factors are driving Open Angle Glaucoma epidemiology trends @ Open Angle Glaucoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Open Angle Glaucoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Open Angle Glaucoma market or expected to get launched during the study period. The analysis covers Open Angle Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Open Angle Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Open Angle Glaucoma Therapies and Key Companies

*
NCX-470: Nicox Ophthalmics

*
PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)/Visiox Pharma

*
TC-002 (latanoprost): TearClear

*
iDose TR (Travoprost Intraocular Implant): Glaukos Corporation

*
Sepetaprost/DE-126/ONO-9054/STN-1012600: Santen Inc/Ono Pharmaceutical

*
Catioprost/DE-130A/STN1013001: Santen Pharmaceuticals

*
Citicoline eye drops 2%: Omikron Italia S.r.l./OPIS Spain

*
H-1337: D. Western Therapeutics Institute (DWTI)

*
OTX-TIC: Ocular Therapeutix, Inc.

*
LL-BMT1: MediPrint Ophthalmics (formerly Leo Lens Pharma)

*
TRS01: Tarsier Pharma

*
POLAT-001 (Liposomal latanoprost): Peregrine Ophthalmic

*
Nyxol (Phentolamine Mesylate): Ocuphire Pharma

*
QLS-101: Qlaris Bio, Inc.

*
BTQ-1902: Betaliq, Inc.

*
VVN539: VivaVision Biotech, Inc.

*
AGN-193408: Abbvie

Discover more about therapies set to grab major Open Angle Glaucoma market share @ Open Angle Glaucoma Treatment Market [https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Open Angle Glaucoma Market Strengths

*
Rising prevalence of Open Angle Glaucoma (OAG) resulting in demand for improved treatments. Growing awareness about the importance of early detection to reduce the disease burden contributes to increased screening and diagnosis rates

Open Angle Glaucoma Market Opportunities

*
With increasing awareness and improving healthcare infrastructure, the Open Angle Glaucoma (OAG) market has growth potential in emerging markets

Scope of the Open Angle Glaucoma Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Open Angle Glaucoma Companies: OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others

*
Key Open Angle Glaucoma Therapies: Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others

*
Open Angle Glaucoma Therapeutic Assessment: Open Angle Glaucoma current marketed and Open Angle Glaucoma emerging therapies

*
Open Angle Glaucoma Market Dynamics: Open Angle Glaucoma market drivers and Open Angle Glaucoma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Open Angle Glaucoma Unmet Needs, KOL's views, Analyst's views, Open Angle Glaucoma Market Access and Reimbursement

To know more about Open Angle Glaucoma companies working in the treatment market, visit @ Open Angle Glaucoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Open Angle Glaucoma Market Report Introduction

2. Executive Summary for Open Angle Glaucoma

3. SWOT analysis of Open Angle Glaucoma

4. Open Angle Glaucoma Patient Share (%) Overview at a Glance

5. Open Angle Glaucoma Market Overview at a Glance

6. Open Angle Glaucoma Disease Background and Overview

7. Open Angle Glaucoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Open Angle Glaucoma

9. Open Angle Glaucoma Current Treatment and Medical Practices

10. Open Angle Glaucoma Unmet Needs

11. Open Angle Glaucoma Emerging Therapies

12. Open Angle Glaucoma Market Outlook

13. Country-Wise Open Angle Glaucoma Market Analysis (2019-2032)

14. Open Angle Glaucoma Market Access and Reimbursement of Therapies

15. Open Angle Glaucoma Market Drivers

16. Open Angle Glaucoma Market Barriers

17. Open Angle Glaucoma Appendix

18. Open Angle Glaucoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=open-angle-glaucoma-market-to-show-remarkable-growth-trends-from-2023-to-2032-delveinsight-reports-visiox-pharma-tearclear-vivavision-biotech-inc-abbvie-ocuphire-pharma-qlaris-bio-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.